» Articles » PMID: 38920356

Genetic Landscape of Atopic Dermatitis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: This review summarizes recent advances in identifying genetic risk factors for atopic dermatitis and how these genetic associations are being used to explore the causal relationships between atopic dermatitis and potential risk factors and downstream outcomes.

Recent Findings: A recent large-scale GWAS meta-analysis has identified 91 genetic loci associated with atopic dermatitis. Rare variant studies have also identified new gain-of-function or loss-of-function variants implicated in atopic dermatitis, particularly for FLG and STAT6/JAK1 . Finally, there has been a surge in utilizing genetic association data to investigate the causal relationships between atopic dermatitis and other traits. Mendelian randomization studies have found that various metabolites and gut microbiota are causal for atopic dermatitis and have causally implicate atopic dermatitis in the development of alopecia areata, diabetes, vascular dementia and some cancers.

Summary: The past year has seen a huge increase in the genes implicated for atopic dermatitis and in the use of genetics to explore causal relationships. The latter requires caution in implementation and interpretation, but is a promising area of research. In the coming years, increasing the ethnic diversity of atopic dermatitis genetic studies would be very welcome and the translation of current genetic findings into new drugs will be an exciting area of development.

References
1.
Huang X, Pang S, Yang L, Han T, Chen J, Huang C . TNFSF14 mediates the impact of docosahexaenoic acid on atopic dermatitis: a Mendelian randomization study. Eur Rev Med Pharmacol Sci. 2024; 28(1):107-117. DOI: 10.26355/eurrev_202401_34896. View

2.
Smits J, van den Brink N, Meesters L, Hamdaoui H, Niehues H, Jansen P . Investigations into the FLG Null Phenotype: Showcasing the Methodology for CRISPR/Cas9 Editing of Human Keratinocytes. J Invest Dermatol. 2023; 143(8):1520-1528.e5. DOI: 10.1016/j.jid.2023.02.021. View

3.
Baris S, Benamar M, Chen Q, Catak M, Martinez-Blanco M, Wang M . Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6. J Allergy Clin Immunol. 2023; 152(1):182-194.e7. PMC: 10330134. DOI: 10.1016/j.jaci.2023.01.023. View

4.
Keam S . Lebrikizumab: First Approval. Drugs. 2024; 84(3):347-353. DOI: 10.1007/s40265-024-02000-z. View

5.
. Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond. Trends Immunol. 2024; 45(2):138-153. DOI: 10.1016/j.it.2023.12.003. View